SG11201909856XA - Mesenchymal lineage precursor or stem cells with enhanced immunosuppression - Google Patents
Mesenchymal lineage precursor or stem cells with enhanced immunosuppressionInfo
- Publication number
- SG11201909856XA SG11201909856XA SG11201909856XA SG11201909856XA SG 11201909856X A SG11201909856X A SG 11201909856XA SG 11201909856X A SG11201909856X A SG 11201909856XA SG 11201909856X A SG11201909856X A SG 11201909856XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- stem cells
- mesenchymal lineage
- lineage precursor
- pct
- Prior art date
Links
- 239000002243 precursor Substances 0.000 title abstract 4
- 210000000130 stem cell Anatomy 0.000 title abstract 4
- 206010062016 Immunosuppression Diseases 0.000 title abstract 2
- 230000001506 immunosuppresive effect Effects 0.000 title abstract 2
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 3
- 208000024908 graft versus host disease Diseases 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 241001006211 Silvius Species 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 238000002659 cell therapy Methods 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 210000001704 mesoblast Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1157—Monocytes, macrophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2523/00—Culture process characterised by temperature
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 November 2018 (08.11.2018) WIPO I PCT omit VIII °nolo Hololloiolimiolionom oimIE (10) International Publication Number WO 2018/202853 Al (51) International Patent Classification: C12N 5/0775 (2010.01) (21) International Application Number: (22) International Filing Date: PCT/EP2018/061503 Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) 04 May 2018 (04.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 2017901633 04 May 2017 (04.05.2017) AU 2017901636 04 May 2017 (04.05.2017) AU 2018900551 21 February 2018 (21.02.2018) AU (71) Applicant: MESOBLAST INTERNATIONAL SARL [CH/CH]; c/o Accounting and Management Services SA, Route de Pre-Bois 20, 1217 Meyrin (CH). (72) Inventors: ITESCU, Silviu; c/o Level 38, 55 Collins Street, Melbourne, Victoria 3000 (AU). SIMMONS, Paul; c/o Level 38, 55 Collins Street, Melbourne, Victoria 3000 (AU). (74) Agent: MULLER, Christian; ZSP Patentanwalte PartG mbB, Hansastr. 32, 80686 Miinchen (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). 00 O (54) Title: MESENCHYMAL LINEAGE PRECURSOR OR STEM CELLS WITH ENHANCED IMMUNOSUPPRESSION 00 (57) : The present disclosure relates to cellular therapy products comprising mesenchymal lineage precursor or stem cells and O potency assay for these products. The present disclosure also relates to methods for treatment of immune or inflammatory disorders, and treatment or prevention of graft versus host disease (GVHD), or one or more symptoms associated with GVHD, by administration C of mesenchymal lineage precursor or stem cells.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017901636A AU2017901636A0 (en) | 2017-05-04 | Method for treating Graft versus Host Disease (GVHD) | |
| AU2017901633A AU2017901633A0 (en) | 2017-05-04 | Potency assay for immunosuppression | |
| AU2018900551A AU2018900551A0 (en) | 2018-02-21 | Potency assay for immunosuppression II | |
| PCT/EP2018/061503 WO2018202853A1 (en) | 2017-05-04 | 2018-05-04 | Mesenchymal lineage precursor or stem cells with enhanced immunosuppression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909856XA true SG11201909856XA (en) | 2019-11-28 |
Family
ID=62222586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909856X SG11201909856XA (en) | 2017-05-04 | 2018-05-04 | Mesenchymal lineage precursor or stem cells with enhanced immunosuppression |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20200325450A1 (en) |
| EP (2) | EP4137562A1 (en) |
| JP (2) | JP7398959B2 (en) |
| KR (2) | KR20240056790A (en) |
| CN (1) | CN110753751A (en) |
| AU (1) | AU2018262788A1 (en) |
| BR (1) | BR112019022901A2 (en) |
| CA (1) | CA3062112A1 (en) |
| SG (1) | SG11201909856XA (en) |
| WO (1) | WO2018202853A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115361960A (en) * | 2020-02-19 | 2022-11-18 | 迈索布拉斯特国际有限公司 | Methods for treating chronic graft versus host disease |
| JP2021136883A (en) * | 2020-03-02 | 2021-09-16 | 株式会社ガイアバイオメディシン | Method for treating highly active nk cells |
| CN112444479B (en) * | 2021-02-01 | 2021-05-07 | 宁波大学 | Single cell mass spectrometry system and method based on parallel processing technology |
| CN113881707B (en) * | 2021-10-25 | 2023-07-14 | 中国人民解放军军事科学院军事医学研究院 | Product, method and application for regulating and controlling immune suppression effect of umbilical cord mesenchymal stem cells |
| WO2023119239A1 (en) * | 2021-12-23 | 2023-06-29 | Mesoblast International Sarl | Method of treating severe graft versus host disease |
| WO2024009226A1 (en) * | 2022-07-05 | 2024-01-11 | Mesoblast International Sarl | Cryopreserved intermediate and potency assay for same |
| WO2024036052A1 (en) | 2022-08-09 | 2024-02-15 | Exxonmobil Chemical Patents Inc. | Methods for preparing diphenylsilane bridged c1 symmetric catalysts and polymers made therefrom |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4593089A (en) | 1980-07-30 | 1986-06-03 | Abbott Laboratories | Fluorescent polarization immunoassay utilizing substituted triazinylaminofluorescein aminoglycosides |
| US4751190A (en) | 1985-07-22 | 1988-06-14 | Abbott Laboratories | Fluorescence polarization immunoassay and reagents for use therein |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| WO1992001070A1 (en) | 1990-07-09 | 1992-01-23 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | High efficiency packaging of mutant adeno-associated virus using amber suppressions |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5486359A (en) | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
| US5837539A (en) | 1990-11-16 | 1998-11-17 | Osiris Therapeutics, Inc. | Monoclonal antibodies for human mesenchymal stem cells |
| CA2115742A1 (en) | 1991-08-20 | 1993-03-04 | Ronald G. Crystal | Adenovirus mediated transfer of genes to the gastrointestinal tract |
| DE4211351A1 (en) | 1992-04-04 | 1993-10-07 | Behringwerke Ag | Method for analyzing particle-enhanced agglutination reactions on centrifugal analyzers by determining the turbidity brightening |
| CA2163129A1 (en) | 1993-05-17 | 1994-11-24 | Flossie Wong-Staal | Ribozyme gene therapy for hiv infection and aids |
| US6541213B1 (en) | 1996-03-29 | 2003-04-01 | University Of Washington | Microscale diffusion immunoassay |
| CA2244326C (en) | 1997-08-11 | 2006-03-28 | Shinichi Eda | Microparticle enhanced light scattering agglutination assay and microparticle reagents therefor |
| US6566051B1 (en) | 1999-01-15 | 2003-05-20 | Medtox Scientific, Inc. | Lateral flow test strip |
| AU2003901668A0 (en) | 2003-03-28 | 2003-05-01 | Medvet Science Pty. Ltd. | Non-haemopoietic precursor cells |
| JP4264348B2 (en) | 2001-08-20 | 2009-05-13 | プロテオム システムズ リミテッド | Diagnostic inspection method and apparatus |
| CA2507415A1 (en) | 2002-11-21 | 2004-06-03 | The University Of Leicester | Bodily fluid markers of tissue hypoxia |
| KR101446634B1 (en) | 2005-04-12 | 2014-10-16 | 메소블라스트, 아이엔씨. | Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase |
| EP1971679B1 (en) * | 2006-01-13 | 2013-04-10 | Osiris Therapeutics, Inc. | Mesenchymal stem cells expressing tnf- receptor |
| ES2831259T3 (en) * | 2010-07-02 | 2021-06-08 | Mesoblast Inc | Treatment of graft versus host disease |
| US20120087933A1 (en) | 2010-10-08 | 2012-04-12 | Samson Tom | Enhanced msc preparations |
| KR20150016117A (en) * | 2013-07-30 | 2015-02-11 | 코아스템(주) | Pharmaceutical Compositions for Preventing or Treating Autoimmune Diseases Comprising Mesenchymal Stem Cells Derived from Human Bone-Marrow |
| US10400218B2 (en) * | 2014-04-07 | 2019-09-03 | Mesoblast International Sarl | Stem cell composition |
| BR112017012911B1 (en) * | 2014-12-23 | 2021-10-05 | Mesoblast International Sàrl | METHOD FOR TREATMENT OF HEART FAILURE |
-
2018
- 2018-05-04 AU AU2018262788A patent/AU2018262788A1/en active Pending
- 2018-05-04 SG SG11201909856X patent/SG11201909856XA/en unknown
- 2018-05-04 EP EP22187395.3A patent/EP4137562A1/en active Pending
- 2018-05-04 KR KR1020247013202A patent/KR20240056790A/en active Search and Examination
- 2018-05-04 JP JP2019560259A patent/JP7398959B2/en active Active
- 2018-05-04 CN CN201880036997.2A patent/CN110753751A/en active Pending
- 2018-05-04 BR BR112019022901A patent/BR112019022901A2/en unknown
- 2018-05-04 US US16/607,293 patent/US20200325450A1/en active Pending
- 2018-05-04 WO PCT/EP2018/061503 patent/WO2018202853A1/en unknown
- 2018-05-04 EP EP18726345.4A patent/EP3619294A1/en active Pending
- 2018-05-04 KR KR1020197035053A patent/KR102660506B1/en active IP Right Grant
- 2018-05-04 CA CA3062112A patent/CA3062112A1/en active Pending
-
2023
- 2023-10-05 JP JP2023173584A patent/JP2023174760A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7398959B2 (en) | 2023-12-15 |
| EP4137562A1 (en) | 2023-02-22 |
| AU2018262788A1 (en) | 2019-11-14 |
| EP3619294A1 (en) | 2020-03-11 |
| KR20200003044A (en) | 2020-01-08 |
| US20200325450A1 (en) | 2020-10-15 |
| CN110753751A (en) | 2020-02-04 |
| KR20240056790A (en) | 2024-04-30 |
| BR112019022901A2 (en) | 2020-05-19 |
| JP2023174760A (en) | 2023-12-08 |
| JP2020518260A (en) | 2020-06-25 |
| WO2018202853A1 (en) | 2018-11-08 |
| CA3062112A1 (en) | 2018-11-08 |
| KR102660506B1 (en) | 2024-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909856XA (en) | Mesenchymal lineage precursor or stem cells with enhanced immunosuppression | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201807573VA (en) | Methods for providing single-stranded rna | |
| SG11201909777YA (en) | Modulatory polynucleotides | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201903928WA (en) | Mesenchymal stem cells populations, their products, and use thereof | |
| SG11201908391XA (en) | Methods for modulating an immune response | |
| SG11201909868YA (en) | Compositions and methods of treating huntington's disease | |
| SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
| SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
| SG11201806639VA (en) | New streptococcal proteases | |
| SG11201900745VA (en) | Substituted thiazolo-pyridine compounds as malt1 inhibitors | |
| SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201909520VA (en) | Rna for treatment of autoimmune diseases | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201808964PA (en) | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene |